OBJECTIVE: Dopamine transporter (DAT) density is considered as a marker of pre-synaptic function. Numerous neuroimaging studies have consistently demonstrated an age-related decrease in DAT density in normal human brain. However, the precise degree of the regional decline is not yet clear. The purpose of this study was to evaluate the effect of the normal aging process on DAT densities in human-specific brain regions including the substantia nigra and thalamus using positron emission tomography (PET) with [(18)F]FE-PE2I, a new PET radioligand with high affinity and selectivity for DAT. METHODS: Thirty-six healthy volunteers ranging in age from 22 to 80 years were scanned with PET employing [(18)F]FE-PE2I for measuring DAT densities. Region of interest (ROI)-based analysis was used, and ROIs were manually defined for the caudate, putamen, substantia nigra, thalamus, and cerebellar cortex. DAT binding was quantified using a simplified reference tissue model, and the cerebellum was used as reference region. Estimations of binding potential in the caudate, putamen, substantia nigra, and thalamus were individually regressed according to age using simple regression analysis. Estimates of DAT loss per decade were obtained using the values from the regression slopes. RESULTS: There were 7.6, 7.7, and 3.4% per-decade declines in DAT in the caudate, putamen, and substantia nigra, respectively. By contrast, there was no age-related decline of DAT in the thalamus. CONCLUSIONS: [(18)F]FE-PE2I allowed reliable quantification of DAT, not only in the caudate and putamen but also in the substantia nigra. From the results, we demonstrated the age-related decline in the caudate and putamen as reported in previous studies, and additionally for those in the substantia nigra for the first time.
OBJECTIVE:Dopamine transporter (DAT) density is considered as a marker of pre-synaptic function. Numerous neuroimaging studies have consistently demonstrated an age-related decrease in DAT density in normal human brain. However, the precise degree of the regional decline is not yet clear. The purpose of this study was to evaluate the effect of the normal aging process on DAT densities in human-specific brain regions including the substantia nigra and thalamus using positron emission tomography (PET) with [(18)F]FE-PE2I, a new PET radioligand with high affinity and selectivity for DAT. METHODS: Thirty-six healthy volunteers ranging in age from 22 to 80 years were scanned with PET employing [(18)F]FE-PE2I for measuring DAT densities. Region of interest (ROI)-based analysis was used, and ROIs were manually defined for the caudate, putamen, substantia nigra, thalamus, and cerebellar cortex. DAT binding was quantified using a simplified reference tissue model, and the cerebellum was used as reference region. Estimations of binding potential in the caudate, putamen, substantia nigra, and thalamus were individually regressed according to age using simple regression analysis. Estimates of DAT loss per decade were obtained using the values from the regression slopes. RESULTS: There were 7.6, 7.7, and 3.4% per-decade declines in DAT in the caudate, putamen, and substantia nigra, respectively. By contrast, there was no age-related decline of DAT in the thalamus. CONCLUSIONS: [(18)F]FE-PE2I allowed reliable quantification of DAT, not only in the caudate and putamen but also in the substantia nigra. From the results, we demonstrated the age-related decline in the caudate and putamen as reported in previous studies, and additionally for those in the substantia nigra for the first time.
Authors: Victoria Kacprzak; Neil A Patel; Elizabeth Riley; Lili Yu; Jing-Ruey J Yeh; Irina V Zhdanova Journal: Pharmacol Biochem Behav Date: 2017-04-10 Impact factor: 3.533
Authors: My Jonasson; Lieuwe Appel; Torsten Danfors; Dag Nyholm; Håkan Askmark; Andreas Frick; Jonas Engman; Tomas Furmark; Jens Sörensen; Mark Lubberink Journal: Am J Nucl Med Mol Imaging Date: 2017-12-20
Authors: Antonio Martín-Bastida; Nicholas P Lao-Kaim; Andreas Antonios Roussakis; Graham E Searle; Yue Xing; Roger N Gunn; Stefan T Schwarz; Roger A Barker; Dorothee P Auer; Paola Piccini Journal: Brain Date: 2019-07-01 Impact factor: 13.501
Authors: Seunghyeon Shin; Hyun-Yeol Nam; Myung Jun Lee; Kyoungjune Pak; Keunyoung Kim; In Joo Kim Journal: Ann Nucl Med Date: 2020-10-14 Impact factor: 2.668
Authors: Christopher T Smith; M Danica San Juan; Linh C Dang; Daniel T Katz; Scott F Perkins; Leah L Burgess; Ronald L Cowan; H Charles Manning; Michael L Nickels; Daniel O Claassen; Gregory R Samanez-Larkin; David H Zald Journal: Transl Psychiatry Date: 2018-12-07 Impact factor: 6.222
Authors: Andreas-Antonios Roussakis; Marta Gennaro; Nicholas P Lao-Kaim; David Towey; Paola Piccini Journal: J Neuroinflamm Neurodegener Dis Date: 2019-06-05
Authors: Susanna Jakobson Mo; Jan Axelsson; Lars Jonasson; Anne Larsson; Mattias J Ögren; Margareta Ögren; Andrea Varrone; Linda Eriksson; David Bäckström; Sara Af Bjerkén; Jan Linder; Katrine Riklund Journal: EJNMMI Res Date: 2018-11-15 Impact factor: 3.138